Free Trial

Elutia (ELUT) Stock Price, News & Analysis

Elutia logo
$3.22 +0.02 (+0.63%)
As of 02:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Elutia Stock (NASDAQ:ELUT)

Key Stats

Today's Range
$3.05
$3.25
50-Day Range
$2.55
$3.40
52-Week Range
$2.28
$5.24
Volume
31,880 shs
Average Volume
45,086 shs
Market Capitalization
$111.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Remove Ads

Elutia Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

ELUT MarketRank™: 

Elutia scored higher than 83% of companies evaluated by MarketBeat, and ranked 175th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elutia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Elutia has only been the subject of 1 research reports in the past 90 days.

  • Read more about Elutia's stock forecast and price target.
  • Earnings Growth

    Earnings for Elutia are expected to grow in the coming year, from ($1.74) to ($0.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elutia is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elutia is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Elutia's valuation and earnings.
  • Percentage of Shares Shorted

    0.29% of the float of Elutia has been sold short.
  • Short Interest Ratio / Days to Cover

    Elutia has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elutia has recently decreased by 29.77%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Elutia does not currently pay a dividend.

  • Dividend Growth

    Elutia does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.29% of the float of Elutia has been sold short.
  • Short Interest Ratio / Days to Cover

    Elutia has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elutia has recently decreased by 29.77%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Elutia has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Elutia this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Elutia to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elutia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,050,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    40.80% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Elutia's insider trading history.
Receive ELUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elutia and its competitors with MarketBeat's FREE daily newsletter.

ELUT Stock News Headlines

Elutia files $100M mixed securities shelf
Lying in hospital… staring at the light
"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.
Elutia Inc. Q4 Loss Decreases
Q4 2024 Elutia Inc Earnings Call
Elutia reports Q4 EPS (26c) vs. (40c) last year
See More Headlines

ELUT Stock Analysis - Frequently Asked Questions

Elutia's stock was trading at $3.74 on January 1st, 2025. Since then, ELUT shares have decreased by 13.9% and is now trading at $3.22.
View the best growth stocks for 2025 here
.

Elutia Inc. (NASDAQ:ELUT) released its quarterly earnings data on Monday, November, 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.19. The company earned $11.49 million during the quarter, compared to the consensus estimate of $11.54 million.

Top institutional shareholders of Elutia include AIGH Capital Management LLC (8.90%), Silverarc Capital Management LLC (5.16%), Birchview Capital LP (3.55%) and Kennedy Capital Management LLC (0.54%). Insiders that own company stock include Highcape Capital, LP, Birchview Capital, Lp, Matthew Ferguson, Thomas Englese, David Colpman and Brigid Makes.
View institutional ownership trends
.

Shares of ELUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elutia investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Jabil (JBL), Meta Platforms (META) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/08/2021
Today
3/18/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELUT
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$10.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+181.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,660,000.00
Net Margins
-218.72%
Pretax Margin
-243.28%

Debt

Sales & Book Value

Annual Sales
$24.38 million
Price / Cash Flow
N/A
Book Value
($1.66) per share
Price / Book
-1.93

Miscellaneous

Free Float
20,461,000
Market Cap
$110.60 million
Optionable
Not Optionable
Beta
0.86
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ELUT) was last updated on 3/18/2025 by MarketBeat.com Staff
From Our Partners